Acrométastases de la main et du pied compliquant un cancer mammaire

Biyi, A.; Oufroukhi, Y.; Doudouh, A.

doi:10.1016/j.main.2009.08.008

Cited by 7 publications

(3 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 10 , 18 , 42 , 51 Breast cancer, instead, is already diagnosed at the time of foot metastasis discovery. 12 , 20 , 21 , 27 , 44 …”

Section: Resultsmentioning

confidence: 99%

“…13,28,29,37 Radiotherapy on the metastasis site, whether alone or pre/post-surgery, was delivered to 27 out of 44 patients, often with palliative purposes. 7,8,12,[14][15][16][17][18][19]21,[25][26][27]31,[34][35][36]42,45,49,50 Systemic therapies, such as chemotherapy, hormonal therapy and biological drugs, were also given to reach a better prognosis for both primary and secondary lesions. Five patients only had palliative care.…”

Section: Treatment and Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Foot metastasis: Current knowledge

et al. 2020

View full text Add to dashboard Cite

Foot metastasis are rare and often overlooked due to non-specifical symptoms. This often leads to misdiagnosis delaying the right diagnosis. Metastatic disease of the foot is rare. Foot pain and swelling may be the presenting symptom of an occult malignancy. If metastatic disease is not kept in the differential diagnosis of foot pain, diagnosis and treatment will be delayed. The purpose of this study was to analyze articles presenting cases of foot metastasis to provide a more accurate incidence of symptomatic foot acrometastasis as well as to review the clinical course and outcomes. Studies were searched on PubMed/Medline from the inception to February 2020. All studies included in the review presented foot metastasis either with or without a known primary tumor. Most of the articles were case reports, to which we added two case reports of foot acrometastasis produced by our Institute. Forty-three studies with a total of 45 patients were included in this review. The literature published mostly concerning case reports about old patients (average age: 63,2), in a late phase of their disease. Lung cancer appeared to be the most common primary tumor, followed by endometrial and breast cancer. In the 36% of the cases foot metastasis were found when the primary site was still unknown. Calcaneus and metatarsal bones were the most common bones involved. Surgical solution is rare, the chosen treatments are often of palliative care. Prognosis was often poor, death occurred within 2 years since the discovery of foot metastasis in about 50% of cases.

show abstract

“… 10 , 18 , 42 , 51 Breast cancer, instead, is already diagnosed at the time of foot metastasis discovery. 12 , 20 , 21 , 27 , 44 …”

Section: Resultsmentioning

confidence: 99%

Section: Treatment and Prognosismentioning

confidence: 99%

Foot metastasis: Current knowledge

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Las metástasis óseas se presentan entre 20 y 30% de los pacientes con diagnóstico de cáncer, siendo el esqueleto axial el área de mayor afección (1). El compromiso óseo distal a codo y rodilla, denominado acrometástasis, es infrecuente representando entre 0.007 y 0.3% de todos los casos (2).…”

Section: Introduccciónunclassified

Acrometástasis de miembros inferiores: Reporte de dos casos

Quintero

Rueda

2015

Acta Med Col

View full text Add to dashboard Cite

Las metástasis óseas distales a codo y rodilla, acrometástasis, son de baja ocurrencia, se asocian a malignidad avanzada y son indicadores de pobre pronóstico; sólo en el 10% de los casos son la primera expresión clínica de la neoplasia. Su reconocimiento es importante ya que se asemejan a enfermedades benignas frecuentes, retardando el diagnóstico y disminuyendo la expectativa de vida de los pacientes. Se presentan dos casos de pacientes con acrometástasis en miembros inferiores; el primero como la manifestación inicial de recidiva de un carcinoma de células renales; y el segundo como parte del extenso compromiso metastásico de un carcinoma de pulmón en su debut.

show abstract